SCHEMBL2884705

SCHEMBL2884705

COc1ccc2cc(C(C)C(=O)Oc3ccc(C(N)=O)cc3)ccc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.66
TDP1 Q9NUW8 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
AKR1C3 P42330 3/20 0.59
AKR1C2 P52895 3/20 0.59
PTGS1 P23219 2/20 0.59
TSHR P16473 2/20 0.59
CDC42 P60953 1/20 0.59
RAC1 P63000 1/20 0.59
CYP1A2 P05177 1/20 0.59
SLC22A6 Q4U2R8 1/20 0.59
LMNA P02545 1/20 0.57
MAPT P10636 1/20 0.57
CYP2C9 P11712 1/20 0.57
ALOX5 P09917 1/20 0.53
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
PARP1 P09874 1/20 0.51
PARP10 Q53GL7 1/20 0.51
PARP2 Q9UGN5 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30881594 1.00 PTGS2 (0.66) PTGS2TDP1L3MBTL1AKR1C3AKR1C2
SCHEMBL29597190 1.00 PTGS2 (0.66) PTGS2TDP1L3MBTL1AKR1C3AKR1C2
SCHEMBL7712563 0.90 TDP1 (0.75) PTGS2TDP1L3MBTL1AKR1C3AKR1C2
Atb-346 SCHEMBL23643163 0.90 PTGS2 (0.63) PTGS2TDP1L3MBTL1AKR1C3AKR1C2
Atb-346 SCHEMBL31566275 0.90 PTGS2 (0.63) PTGS2TDP1L3MBTL1AKR1C3AKR1C2
Atb-346 SCHEMBL29358559 0.90 PTGS2 (0.63) PTGS2TDP1L3MBTL1AKR1C3AKR1C2
Atb-346 SCHEMBL29596141 0.90 PTGS2 (0.63) PTGS2TDP1L3MBTL1AKR1C3AKR1C2
Atb-346 SCHEMBL2883303 0.90 PTGS2 (0.63) PTGS2TDP1L3MBTL1AKR1C3AKR1C2
SCHEMBL14962625 0.86 TDP1 (0.61) PTGS2TDP1L3MBTL1AKR1C3AKR1C2
SCHEMBL18818204 0.85 PTGS2 (0.68) PTGS2TDP1L3MBTL1AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025076616-A1 POLYMORPHIC FORMS OF OTENAPROXESUL AND COMPOSITIONS AND USES THEREOF ANTIBE THERAPEUTICS INC. (CA) 2025-04-17 WO disclosed
WO-2022115952-A1 [1-(4-CHLORO-BENZOYL)-5-METHOXY-2-METHYL-1H-INDOL-3-YL]-ACETIC ACID 4-THIOCARBAMOYL-PHENYL ESTER FOR THE TREATMENT OF A VIRAL INFECTION ANTIBE THERAPEUTICS INC. (CA) 2022-06-09 WO disclosed
CN-101501018-B Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC 2014-08-27 CN disclosed
US-8541398-B2 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC. (CA) 2013-09-24 US disclosed
US-8541398-B2 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC. (CA) 2013-09-24 US disclosed
US-8541398-B2 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC. (CA) 2013-09-24 US disclosed
EP-2057139-B1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC (US) 2013-09-04 EP disclosed
US-8314140-B2 4-hydroxythiobenzamide derivatives of drugs ANTIBE THERAPEUTICS INC. (CA) 2012-11-20 US disclosed
US-8314140-B2 4-hydroxythiobenzamide derivatives of drugs ANTIBE THERAPEUTICS INC. (CA) 2012-11-20 US disclosed
US-8314140-B2 4-hydroxythiobenzamide derivatives of drugs ANTIBE THERAPEUTICS INC. (CA) 2012-11-20 US disclosed
US-20090306412-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS ANTIBE THERAPEUTICS INC. (CA) 2009-12-10 US disclosed
CN-101501018-A Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs ANTIBE THERAPEUTICS INC (CA) 2009-08-05 CN disclosed
CN-101490029-A 4-hydroxythiobenzamide derivatives of drugs ANTIBE THERAPEUTICS INC (CA) 2009-07-22 CN disclosed
EP-2057139-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS Antibe Therapeutics Inc. (US) 2009-05-13 EP disclosed
EP-2041108-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS Antibe Therapeutics Inc. (US) 2009-04-01 EP disclosed
WO-2008009118-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-24 WO disclosed
WO-2008009127-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-24 WO disclosed
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-03 US disclosed
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-03 US disclosed
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306412-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS HRH4, HRH2, HNMT PTGS2 125/4885TDP1 2411/4885L3MBTL1 2932/4885
US-20080004245-A1 HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS PTGS1, HPGDS, PTGES PTGS2 4/4885TDP1 4498/4885L3MBTL1 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.